MTOR and non-small cell lung carcinoma: Rosiglitazone, for example, was reported toreduce the phosphorylation of Akt, an upstream positive modulator of mTOR, andincrease PTEN, a negative modulator of mTOR, in NSCLC H1792 and H1838 cells;this resulted in inhibition of cell proliferation [87] (Figure 2).